244 related articles for article (PubMed ID: 24338003)
1. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
[TBL] [Abstract][Full Text] [Related]
2. [Methodology and limitations of pre-clinical models for the development of anticarcinogenic chemotherapy combinations].
Vassal G
Bull Cancer; 1998 Nov; 85(11):929-34. PubMed ID: 9951420
[TBL] [Abstract][Full Text] [Related]
3. Evaluating response to antineoplastic drug combinations in tissue culture models.
Reynolds CP; Maurer BJ
Methods Mol Med; 2005; 110():173-83. PubMed ID: 15901935
[TBL] [Abstract][Full Text] [Related]
4. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.
Harasym TO; Liboiron BD; Mayer LD
Methods Mol Biol; 2010; 596():291-323. PubMed ID: 19949929
[TBL] [Abstract][Full Text] [Related]
5. Combinations of targeted therapies in human cancers.
Decaudin D; Le Tourneau C
Aging (Albany NY); 2016 Oct; 8(10):2258-2259. PubMed ID: 27783563
[No Abstract] [Full Text] [Related]
6. Molecular-targeted agents combination therapy for cancer: developments and potentials.
Li F; Zhao C; Wang L
Int J Cancer; 2014 Mar; 134(6):1257-69. PubMed ID: 23649791
[TBL] [Abstract][Full Text] [Related]
7. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro.
Chou TC
Contrib Gynecol Obstet; 1994; 19():91-107. PubMed ID: 7995057
[No Abstract] [Full Text] [Related]
8. A high-throughput yeast assay identifies synergistic drug combinations.
Torres NP; Lee AY; Giaever G; Nislow C; Brown GW
Assay Drug Dev Technol; 2013 Jun; 11(5):299-307. PubMed ID: 23772551
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
10. Strategies for optimizing combinations of molecularly targeted anticancer agents.
Dancey JE; Chen HX
Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303
[TBL] [Abstract][Full Text] [Related]
11. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Mayer LD; Harasym TO; Tardi PG; Harasym NL; Shew CR; Johnstone SA; Ramsay EC; Bally MB; Janoff AS
Mol Cancer Ther; 2006 Jul; 5(7):1854-63. PubMed ID: 16891472
[TBL] [Abstract][Full Text] [Related]
12. Preclinical modeling of combination treatments: fantasy or requirement?
Decker S; Sausville EA
Ann N Y Acad Sci; 2005 Nov; 1059():61-9. PubMed ID: 16382044
[TBL] [Abstract][Full Text] [Related]
13. Binary/ternary combined effects of vitamin K3 with other antitumor agents in nasopharyngeal carcinoma CG1 cells.
Liao WC; Wu FY; Wu CW
Int J Oncol; 2000 Aug; 17(2):323-8. PubMed ID: 10891542
[TBL] [Abstract][Full Text] [Related]
14. Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis.
Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
PLoS One; 2019; 14(1):e0211268. PubMed ID: 30695050
[TBL] [Abstract][Full Text] [Related]
15. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.
Wali VB; Langdon CG; Held MA; Platt JT; Patwardhan GA; Safonov A; Aktas B; Pusztai L; Stern DF; Hatzis C
Cancer Res; 2017 Jan; 77(2):566-578. PubMed ID: 27872098
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro.
Budman DR; Tai J; Calabro A
Breast Cancer Res Treat; 2007 Jul; 104(1):93-101. PubMed ID: 17004104
[TBL] [Abstract][Full Text] [Related]
17. Methods for High-throughput Drug Combination Screening and Synergy Scoring.
He L; Kulesskiy E; Saarela J; Turunen L; Wennerberg K; Aittokallio T; Tang J
Methods Mol Biol; 2018; 1711():351-398. PubMed ID: 29344898
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Pinto AC; Moreira JN; Simões S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
[TBL] [Abstract][Full Text] [Related]
19. Combining molecular targeted therapies: clinical experience.
Pivot X; Bedairia N; Thiery-Vuillemin A; Espie M; Marty M
Anticancer Drugs; 2011 Sep; 22(8):701-10. PubMed ID: 21467916
[TBL] [Abstract][Full Text] [Related]
20. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
Menden MP; Wang D; Mason MJ; Szalai B; Bulusu KC; Guan Y; Yu T; Kang J; Jeon M; Wolfinger R; Nguyen T; Zaslavskiy M; ; Jang IS; Ghazoui Z; Ahsen ME; Vogel R; Neto EC; Norman T; Tang EKY; Garnett MJ; Veroli GYD; Fawell S; Stolovitzky G; Guinney J; Dry JR; Saez-Rodriguez J
Nat Commun; 2019 Jun; 10(1):2674. PubMed ID: 31209238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
